COMPOSITION AND METHOD FOR THE PROTECTION OF ARTICULAR CARTILAGE

COMPOSITION ET METHODE DE PROTECTION DU CARTILAGE ARTICULAIRE

English Abstract

The novel therapeutic potential of Calebin A and compositions thereof to prevent pathological damage to mammalian articular cartilage is disclosed. Specifically a method has been provided for protecting mammalian articular cartilage from pathological damage, said method comprising the step of administering effective dose of Calebin A to mammals in need of said protection.

French Abstract

L'invention concerne la nouvelle possibilité thérapeutique de la calébine A et des compositions associées pour prévenir les lésions pathologiques du cartilage articulaire chez le mammifère. L'invention concerne plus précisément une méthode permettant de protéger le cartilage articulaire chez le mammifère de lésions pathologiques, ladite méthode consistant à administrer une dose efficace de calébine A aux mammifères à protéger.

Claims

We claim
1. Use of Calebin A in effective amounts to protect mammalian articular
cartilage from
pathological damage in a mammal in need of said protection.
2. Use of Calebin A for the manufacture of a medicament for protecting
articular cartilage
from pathological damage in a mammal in need of said protection.

Description

CA 02935898 2016-07-05
WO 2015/105501 PCT/US2014/010993
COMPOSITION AND METHOD FOR THE PROTECTION OF ARTICULAR CARTILAGE
BACKGROUND OF THE INVENTION
[Para 001] Field of the invention
[Para 002] The present invention in general pertains to protective
compositions and methods
thereof for articular cartilage. Specifically, the present invention pertains
to the potential of
Calebin A to prevent pathological damage to articular cartilage.
[Para 003] Description of prior art
[Para 0041 Articular cartilage is a specialized connective tissue that covers
the articular surfaces
of bones forming a synovial joint. Articular cartilage endows the synovial
joints the ability to
provide low friction and relatively pain free motion. Articular cartilage
structures and functions
are prone to damage following trauma (fall or accident), wear and tear and
underlying
pathological disease conditions. Articular cartilage tissue usually does not
regenerate (the
process of self repair) after injury or disease leading to loss of tissue and
formation of a defect.
Reasons attributed to such non-regeneration include (i) Fewer cellular
components; (ii) poor
metabolism and (iii) the restricted capacity of innate chondrocytes to divide
and migrate in the
tissue on account of dense matrix fibers. Thus, active principles that are
capable of protecting
articular cartilage from damage due to trauma and disease constitute important
technological
areas that offer considerable scope to improve the quality of life of
individuals who are prone
to such trauma.
[Para 005] It is the principle of the present invention to disclose the
potential of Calebin A and
compositions thereof to prevent pathological damage to mammalian articular
cartilage.
[Para 006] The present invention fulfills the aforesaid objective and provides
further related
advantages.
SUMMARY OF THE INVENTION
[Para 0071 The present invention relates to the potential of Calebin A and
compositions thereof
to prevent pathological damage to mammalian articular cartilage.
[Para 008] The present invention provides the following advantage.
1. Disclosure of the novel therapeutic potential of Calebin A and compositions
thereof to
prevent pathological damage to mammalian articular cartilage.
[Para 009] Other features and advantages of the present invention will become
apparent from
the following more detailed description, taken in conjunction with the
accompanying images,
which illustrate, by way of example, the principle of the invention.
1

CA 02935898 2016-07-05
WO 2015/105501 PCT/US2014/010993
BRIEF DESCRIPTION OF THE FIGURES
[Para 0010] Fig.1 shows the histopathology of the rat paw tissue section of
arthritic control
group.
[Para 0011] Fig.2 shows the histopathology of the rat paw tissue section of
the group treated
with Calebin A (10 mg/kg).
[Para 0012] Fig.3 shows the histopathology of the rat paw tissue section of
the group treated
with Calebin A (20 mg/kg).
DETAILED DESCRIPTION OF THE MOST PREFERRED EMBODIMENT
(Figs.1, 2 and 3)
[Para 0013] In the most preferred embodiment, the present invention relates to
a method of
using Calebin A in effective amounts to protect mammalian articular cartilage
from pathological
damage, said method comprising the step of administering effective dose of
Calebin A to
mammals in need of said protection.
[Para 0014] In another preferred embodiment, the present invention relates to
the method of
protecting mammalian articular cartilage from pathological damage, said method
comprising
the step of administering effective dose of Calebin A to mammals in need of
said protection.
[Para 0015] The novel therapeutic potential of Calebin A and compositions
thereof to prevent
pathological damage to mammalian articular cartilage is clearly enunciated in
the illustrative
examples discussed herein below.
[Para 0016] Illustrative Example 1
[Para 0017] Pathological damage: Adjuvant induced arthritis in animal models
[Para 0018] Animals used: Albino Wistar rats of either sex
[Para 0019] Weight of the animals: 140-180 grams
[Para 0020] Number of animals/group: 05
[Para 0021] Methodology: Chronic arthritis was induced in rats by the
injection of 0.05mL of
(0.5% w/v) suspension of killed Mycobacterium tuberculosis, homogenized in
liquid paraffin in
the left hind foot.
Table A
Scheme of work for screening of
Calebin A in Mycobacterium tuberculosis (adjuvant) induced arthritis in
mammals
Animal Group Test compound Treatment
Group 1 Naïve control Vehicle
Group 2 Arthritic control
Vehicle + 0.5% w/v adjuvant
2

CA 02935898 2016-07-05
WO 2015/105501
PCT/US2014/010993
Group 3 Acetyl salicylic acid (ASA) 100
ASA+0.5% w/v adjuvant
mg/kg. (per oral)
Calebin A
Group 4 2.5 mg/kg (per oral
Test compound + 0.5% w/v
administration) adjuvant
Group 5 5 mg/kg (per oral
Test compound + 0.5% w/v
administration) adjuvant
Group 6 10 mg/kg (per oral
Test compound + 0.5% w/v
administration) adjuvant
Group 7 20 mg/kg (per oral
Test compound + 0.5% w/v
administration) adjuvant
[Para 0022] Histopathology:
[Para 00231 Right ankle joints of the animals in the control and treated
groups were separated
from the hind paw, weighed and immersed in 10% buffered formalin for 24 hours,
followed by
decalcification in 10% EDTA, The joints were then dehydrated, processed and
paraffin (56C-58C)
blocks were prepared, stained (hematoxylin and eosin) and examined under the
compound
microscope (Patel P, Patel D, Patel N. Experimental investigation of anti-
rheumatoid activity of
Pleurotus sajorcaju in adjuvant-induced arthritic rats. Chinese Journal of
Natural Medicines,
2012; 10 (4): 0269-0274.
[Para 0024] Histopathology results:
[Para 0025] The rat paw tissue of the control arthritic group showed (Fig.1)
focally damaged
articular cartilage with synovial tissue (Arrows). The articular cartilage and
synovial tissue were
replaced by abundant eosinophilic caeseous necrosis with scattered epitheloid
cells and there
were few poorly formed ill-defined granulomas.
[Para 0026] The rat paw tissue of the group treated with Calebin A (10 mg/kg)
[Fig.2] showed
intact articular cartilage with synovial tissue in the joint. The synovial
tissue consisted of
congested vascular spaces (Long-Arrows), scattered lymphocytes (Short-Arrow)
and intact
synovial lining. No granulomas were seen.
[Para 0027] The rat paw tissue of the group treated with Calebin A (20 mg/kg)
[Fig.3] showed
intact articular cartilage with synovial tissue in the joint. The synovial
tissue consisted of mild
synovial epithelial hyperplasia (Short-Arrow), scattered lymphocytes (Long-
Arrow) and intact
vascular spaces. No granulomas were seen.
[Para 0028] The histopathological studies of arthritic rats shows dose
dependant protection of
articular cartilage with Calebin A.
[Para 0029] While the invention has been described with reference to a
preferred embodiment,
it is to be clearly understood by those skilled in the art that the invention
is not limited thereto.
3

CA 02935898 2016-07-05
WO 2015/105501 PCT/US2014/010993
Rather, the scope of the invention is to be interpreted only in conjunction
with the appended
claims.
4